Kristie L. Kahl

Researchers from Texas A&M University found that circadian rhythms may be key in the timing of when chemotherapy is administered to patients with glioblastoma.

Hodgkin lymphoma survivors may be more likely to develop subsequent estrogen receptor (ER)-negative or -positive breast cancer compared to the general population.

To help educate patients and enable health care teams to effectively manage these side effects, the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) issued new guidelines on understanding and managing immunotherapy-related toxicities.

An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.

After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian cancer to understand just that.

The availability of sexual aids and resources available to cancer survivors at a wide array of cancer centers appeared disappointingly low, according to survey results to be presented at the 2018 Cancer Survivorship Symposium.

Should women who are not known to have a hereditary risk for ovarian cancer get screened? The US Preventive Services Task Force says no.

“Our take home message here is that all women receiving lymph node dissection, whether it is axillary or sentinel, should receive physical therapy to regain range of motion more quickly after surgery, and thus, help maintain physical functioning,” said Electra D. Paskett, Ph.D., MO.

Medicaid expansion reduced the rate of uninsured patients with testicular cancer, and in particular, enabled more men to have earlier stage diagnoses.

Patients with diabetes are at a greater risk for bladder cancer, and worse, for disease recurrence and progression. So, recent research investigated if a certain diet would help.

More than 12 percent of men with prostate cancer tested positive for hereditary mutations of cancer-causing genes, according to study results presented at the 2018 Genitourinary Cancers Symposium.

Germ cell tumors are growths that form from reproductive cells, which can be malignant or benign. In men, these tumors typically form in the testicles. The plus side is these tumors tend to respond well to treatment, even when diagnosed at later stages. However, one problem still persists after a cure.

Although hot flashes are most commonly associated with menopause, this uncomfortable feeling can also be a side effect that occurs in patients with cancer who are being treated with hormone therapy.

A recent study highlighted the additional psychological effects that patients with locally advanced cutaneous melanoma go through, particularly because their lesions are a visible part of their everyday life.

In recent years, major advances have been made in the immunotherapy scape, as it has become instrumental in revolutionizing the way oncologists treat a variety of cancers. However, its success in patients with brain cancer has been extremely limited.

“Regardless of their prognosis, they want to live, and they want to live their normal life. They don’t want it to be what defines them and live their life to the fullest. So, that is where technology can really be helpful," said Savitiri Basavaiah, of Pfizer Oncology.

As genetic testing becomes more accessible with advanced technology and decreased costs, population-based testing for breast and ovarian cancer may be more cost effective in the long run, according to study results published in Journal of the National Cancer Institute.

Kymriah, which is the first FDA-approved CAR-T cell therapy, is showing promising results in pediatric patients with acute lymphoblastic leukemia.

As the Philadelphia Eagles and New England Patriots fight for claim over the Super Bowl trophy tonight, two lung cancer survivor advocates are in Minneapolis fighting for another reason: to raise research and awareness dollars.

Microsatellite instability (MSI) status appeared to have no association with outcomes in patients with liver metastases that spread from colorectal cancer (CRC), according to results from an international, multi-institutional analysis presented at the 2018 Gastrointestinal Cancers Symposium.

“Adding HIPEC to interval debulking improved both recurrence free survival and overall survival without increasing morbidity,” said van Driel.

After patients have exhausted all therapeutic options in their cancer treatment, oftentimes there is nowhere left for them to turn. Despite a terminal diagnosis, some patients may have more options in their remaining days if one bill is passed – if only it were that easy.

Brain HQ, founded by Posit Science, is a computerized brain training program, designed to improve speed of processing information and accuracy in the brain.

Additional physical and mental components may seriously affect health-related quality of life in older patients with cancer.

Because physical activity after diagnosis has proven to lower mortality rates in these patients, it is important to implement feasible and acceptable interventions after CRC diagnoses.

CURE spoke with Scott Paulson, M.D., medical oncologist with Texas Oncology, an affiliate of The US Oncology Network, to break down exactly what MSI-H status is, and the effects it may have on certain malignancies.

As costs decrease, and physicians move to address barriers to genetic testing, a panel of physicians, researchers and a patient advocate highlighted the importance for people to get tested.

Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.

Patients previously treated for DNA mismatch repair (MMR)-deficient/microsatellite instability-high (MSI-H) metastatic colorectal cancer may have a new effective treatment option.

Texas Rangers third-base coach Tony Beasley teams up with Fight CRC, sharing his journey into survivorship and inspiring others in their fight against cancer.